BenevolentAI
cash runway beyond providing capital for next stage of growth cash runway use of proceeds pro cash of provides runway beyond cash cash held in trust pipe transaction fees total pro cash completion of phase i trial for atopic dermatitis and subsequent out license completion of phase i trial for in ulcerative colitis and commencement of phase trial in up to further phase i trials and by a technology platform continually innovating to accelerate our global leadership in enabled drug discovery a platform capable of delivering per year from onwards sufficient | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
35 of 42
Similar slides by BenevolentAI
See diffirences between slides (animation)
Investor Presentation
June 2022
cash runway to at least end providing sufficient capital for next stage of growth | BenevolentAI
Related slides by other companies
Equillium
Investor Presentation
December 2023
milestones | Equillium
Equillium
Investor Presentation
February 2024
milestones | Equillium
Aeglea BioTherapeutics
Investor Presentation
October 2023
cash and anticipated milestones | Aeglea BioTherapeutics
Equillium
Investor Presentation
August 2023
milestones | Equillium
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io